CRISPR Therapeutics AG

NasdaqGM:CRSP Voorraadrapport

Marktkapitalisatie: US$4.0b

CRISPR Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van CRISPR Therapeutics is gedaald met een gemiddeld jaarlijks percentage van -27%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 19.1%. De inkomsten zijn daalde met een gemiddeld percentage van 7% per jaar.

Belangrijke informatie

-27.0%

Groei van de winst

-25.1%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.0%
Inkomstengroei-7.0%
Rendement op eigen vermogen-12.4%
Nettomarge-118.1%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism

Nov 11

Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results

Nov 07
Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results

Crispr Therapeutics: Poised For A Major Turnaround

Oct 28

CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected

Oct 02
CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected

Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres

Sep 13

Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation

Sep 04
Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation

Crispr's Casgevy Launch: Promising Start, Uncertain Future

Aug 14

A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Aug 09
A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential

Aug 07

Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle

Jul 13

Crispr Therapeutics: Beaten Down But Not Broken

Jul 07

CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk

Jun 18
CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk

Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)

Jun 10

Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)

Jun 03

Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being

May 23
Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being

Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts

May 13
Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts

We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn

May 10
We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn

Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg

May 09

Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)

May 03

Crispr Therapeutics: Now Is The Time To Buy

Apr 24

Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Apr 16
Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape

Mar 26

There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump

Feb 22
There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump

Crispr Therapeutics: Cautiously Optimistic

Feb 22

Crispr Therapeutics: Investors Bet Against Casgevy Uptake

Feb 01

Crispr Therapeutics: Commercial Validation Is The Next Step

Jan 18

Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry

Jan 11

CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing

Dec 25
CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing

CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

Nov 02
CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Oct 05
A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price

Sep 14
CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price

We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate

Jul 24
We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate

Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

Jun 28
Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)

CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

Apr 02
CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans

CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price

Mar 06
CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price

Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth

Dec 08
Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth

CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag

Sep 28

Crispr: Elucidating And Forecasting Key Developments

Sep 21

Opbrengsten en kosten

Hoe CRISPR Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqGM:CRSP Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 24203-240710
30 Jun 24202-266720
31 Mar 24272-217720
31 Dec 23371-154760
30 Sep 23170-354810
30 Jun 23170-416900
31 Mar 23100-524970
31 Dec 221-6501020
30 Sep 2214-6811050
30 Jun 2215-6331020
31 Mar 229153121030
31 Dec 219153781000
30 Sep 219024121020
30 Jun 219024471000
31 Mar 211-392930
31 Dec 201-349860
30 Sep 2077-211800
30 Jun 2028920740
31 Mar 2028946680
31 Dec 1929067630
30 Sep 19213-11630
30 Jun 191-200570
31 Mar 192-185540
31 Dec 183-165480
30 Sep 1835-117430
30 Jun 1837-91410
31 Mar 1840-75360
31 Dec 1741-68360
30 Sep 1711-51350
30 Jun 1710-41310
31 Mar 177-36320
31 Dec 165-23310
30 Sep 163-53250
30 Jun 162-44240
31 Mar 161-31170
31 Dec 150-26130

Kwaliteitswinsten: CRSP is momenteel verliesgevend.

Groeiende winstmarge: CRSP is momenteel verliesgevend.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: CRSP is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 27% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van CRSP over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: CRSP is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).


Rendement op eigen vermogen

Hoge ROE: CRSP heeft een negatief Return on Equity ( -12.35% ), omdat het momenteel verliesgevend is.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden